We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

The Pipeline

Cancer affects millions. It cuts across languages, cultures, and family histories. As a cancer community we do what we can. But there’s always that question ringing in our ears, “could we do more?”

The Exact Sciences pipeline is expanding at a rapid pace. We’re taking the same innovative problem-solving approach that resulted in the multitarget stool DNA test (Cologuard) to tackle a wide array of cancer screening challenges. We’re also leveraging the success and impact of the Oncotype IQ portfolio of tests to transform patient treatment decisions. Through our pipeline efforts, we aim to give patients and physicians confidence, while helping to provide smart answers at every step of the cancer journey.


  • Building a cancer detection platform upon learnings from the development of Cologuard
  • Expanding the Oncotype IQ platform to include liquid and tissue-based tests, all with the goal of making cancer care smarter
  • Adapting biomarker-based technologies create a liquid biopsy capable of detecting cancers and precancers from a blood sample
  • Using our proven multimarker approach to achieve analytical sensitivity needed to discriminate between normal and cancerous samples
  • Collaborating with world-class clinicians and scientists at Mayo Clinic to identify biomarkers associated with the 15 deadliest cancers


A new approach for early-stage HCC detection

Liver cancer is the fastest-growing cause of cancer-related death in the United States. By 2035, it is expected to be a third leading cause of cancer-related death, surpassing breast and prostate cancer.1

Outcomes for hepatocellular carcinoma (HCC), the most common type of liver cancer, are improved with early-stage detection. However, most cases of HCC are detected in late stages when curative treatments are no longer an option.2,3

The OncoguardTM Liver solution includes a sophisticated, yet simple, single blood test that delivers advanced sensitivity and specificity to aid consistent and reliable HCC detection. The test is complemented by a Patient Engagement Program designed to help empower patients to proactively protect their health and follow through with routine testing. The OncoguardTM Liver solution is designed with the hope of bringing better outcomes within reach for more patients at risk for HCC.

Simplifying testing to improve outcomes

Developed in collaboration with the Mayo Clinic, OncoguardTM Liver test offers a new way to approach and detect early-stage HCC.


1Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Network Open. 2021;4(4):e214708. doi:10.1001/jamanetworkopen.2021.4708

2Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi: 10.1371/journal.pmed.1001624.

3Choi DT, Kum HC, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019;17(5):976-987.e4. doi: 10.1016/j.cgh.2018.10.031.


“So much of the progress we’ve made so far can be characterized as an amalgamation of solving problems, every step of the way. Why not continue to apply this approach as we pursue a pipeline of early cancer detection tests?”

Dr. Graham Lidgard

Chief Science Officer